Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial
Jenkin D., Wright D., Folegatti PM., Platt A., Poulton I., Lawrie A., Tran N., Boyd A., Turner C., Gitonga JN., Karanja HK., Mugo D., Ewer KJ., Bowden TA., Gilbert SC., Charleston B., Kaleebu P., Hill AVS., Warimwe GM.